Document is current

Article History

Received: 29 August 2024

Accepted: 25 January 2025

First Online: 19 February 2025

Declarations

:

: This study was approved by the Ethics Committees of the Medical University of Vienna (approval no. 1692/2022, 1895/2022).

: Not applicable.

: M.J.M. received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre. A.S.B. received research support from Daiichi Sankyo, Roche, and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. Z.S. is a former employee of Boehringer Ingelheim and Turbine AI. M.P. received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. J.N.K declares consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore he holds shares in StratifAI GmbH, Germany, has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius.